Keywords: |
unclassified drug; gene mutation; cancer risk; cancer incidence; cancer prevention; ovary cancer; breast cancer; prevalence; genetic association; editorial; brca1 protein; brca2 protein; protein p53; risk assessment; genetic susceptibility; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; cancer registry; checkpoint kinase 2; genetic screening; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; inheritance; brca3 protein; poly(adenosine diphosphate ribose)polymerase inhibitor
|